Abstract

Humanizing Models of Liver Diseases

Linda Griffith, Professor, Massachusetts Institute of Technology

The growing commercial availability of high quality cryopreserved human hepatocytes, expansion of hepatocytes via organoid technology, and advances in derivation of hepatic organoids from iPSC, along with advances in mesofluidic platforms that provide gut-liver interactions, open opportunities for building accessible human disease models.   This talk will describe conceptual and technical considerations in building models of liver metabolic and inflammatory diseases, including cell sourcing, culture media design, microphysiological system platform design, incorporation of immune cells, and cross talk with the gut with examples illustrating how to integrate multi-omic data.